Search Results - "Zhu, Andrew X."

Systemic therapies for intrahepatic cholangiocarcinoma by Kelley, Robin Kate, Bridgewater, John, Gores, Gregory J., Zhu, Andrew X.

“…Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare…”
Get full text

Evolution of Systemic Therapy for Hepatocellular Carcinoma by Finn, Richard S., Zhu, Andrew X.

“…Despite being one of the leading causes of cancer death globally, hepatocellular carcinoma (HCC) has historically not been the focus of novel drug development…”
Get full text

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities by Hack, Stephen P, Zhu, Andrew X, Wang, Yulei

“…Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the…”
Get full text

Forty‐Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise by Saha, Supriya K., Zhu, Andrew X., Fuchs, Charles S., Brooks, Gabriel A.

“…Background. Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly…”
Get full text

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases by Marrero, Jorge A., Kulik, Laura M., Sirlin, Claude B., Zhu, Andrew X., Finn, Richard S., Abecassis, Michael M., Roberts, Lewis R., Heimbach, Julie K.

Get full text

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances by Sirica, Alphonse E., Gores, Gregory J., Groopman, John D., Selaru, Florin M., Strazzabosco, Mario, Wei Wang, Xin, Zhu, Andrew X.

“…Intrahepatic cholangiocarcinoma (iCCA) has over the last 10‐20 years become the focus of increasing concern, largely due to its rising incidence and high…”
Get full text

Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma by Galle, Peter R., Foerster, Friedrich, Kudo, Masatoshi, Chan, Stephen L., Llovet, Josep M., Qin, Shukui, Schelman, William R., Chintharlapalli, Sudhakar, Abada, Paolo B., Sherman, Morris, Zhu, Andrew X.

“…Hepatocellular carcinoma (HCC) is one of the most common causes of cancer‐related deaths globally due, in part, to the majority of patients being diagnosed…”
Get full text

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma by GOYAL, Lipika, MUZUMDAR, Mandar D, ZHU, Andrew X

“…Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and mortality worldwide. Despite improvements in local therapies, including…”
Get full text

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference by Llovet, Josep M., Villanueva, Augusto, Marrero, Jorge A., Schwartz, Myron, Meyer, Tim, Galle, Peter R., Lencioni, Riccardo, Greten, Tim F., Kudo, Masatoshi, Mandrekar, Sumithra J., Zhu, Andrew X., Finn, Richard S., Roberts, Lewis R.

Get full text

Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma by Shigeta, Kohei, Datta, Meenal, Hato, Tai, Kitahara, Shuji, Chen, Ivy X., Matsui, Aya, Kikuchi, Hiroto, Mamessier, Emilie, Aoki, Shuichi, Ramjiawan, Rakesh R., Ochiai, Hiroki, Bardeesy, Nabeel, Huang, Peigen, Cobbold, Mark, Zhu, Andrew X., Jain, Rakesh K., Duda, Dan G.

“…Background and Aims Activation of the antitumor immune response using programmed death receptor‐1 (PD‐1) blockade showed benefit only in a fraction of patients…”
Get full text

Comparison of hepatocellular carcinoma in Eastern versus Western populations by Choo, Su Pin, Tan, Wan Ling, Goh, Brian K. P., Tai, Wai Meng, Zhu, Andrew X.

“…Hepatocellular carcinoma (HCC) is a heterogeneous disease that remains highly prevalent in many Asian countries and is the second most common cause of…”
Get full text

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline by Gordan, John D, Kennedy, Erin B, Abou-Alfa, Ghassan K, Beg, Muhammad Shaalan, Brower, Steven T, Gade, Terence P, Goff, Laura, Gupta, Shilpi, Guy, Jennifer, Harris, William P, Iyer, Renuka, Jaiyesimi, Ishmael, Jhawer, Minaxi, Karippot, Asha, Kaseb, Ahmed O, Kelley, R Kate, Knox, Jennifer J, Kortmansky, Jeremy, Leaf, Andrea, Remak, William M, Shroff, Rachna T, Sohal, Davendra P S, Taddei, Tamar H, Venepalli, Neeta K, Wilson, Andrea, Zhu, Andrew X, Rose, Michal G

“…To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC). ASCO…”
Get full text

Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma by Zhu, Andrew X, Dayyani, Farshid, Yen, Chia-Jui, Ren, Zhenggang, Bai, Yuxian, Meng, Zhiqiang, Pan, Hongming, Dillon, Paul, Mhatre, Shivani K, Gaillard, Vincent E, Hernandez, Sairy, Kelley, Robin Kate, Sangro, Bruno

“…Atezolizumab + bevacizumab is the new standard of care for systemic treatment-naïve, unresectable hepatocellular carcinoma (HCC). This exploratory study…”
Get full text

Biology of IDH mutant cholangiocarcinoma by Wu, Meng‐Ju, Shi, Lei, Merritt, Joshua, Zhu, Andrew X., Bardeesy, Nabeel

“…Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes across human cancers. These hotspot gain‐of‐function mutations…”
Get full text

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma by Zhu, Andrew X.

“…It is well appreciated that hepatocellular carcinoma (HCC) represents one of the most challenging malignancies of worldwide importance. In fact, HCC is the…”
Get full text

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets by Chong, Dawn Q, Zhu, Andrew X

“…Cholangiocarcinoma (CCA) is a relatively rare malignancy that arises from the epithelial cells of the intrahepatic, perihilar and distal biliary tree…”
Get full text

CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice by Chen, Yunching, Ramjiawan, Rakesh R., Reiberger, Thomas, Ng, Mei R., Hato, Tai, Huang, Yuhui, Ochiai, Hiroki, Kitahara, Shuji, Unan, Elizabeth C., Reddy, Tejaswini P., Fan, Christopher, Huang, Peigen, Bardeesy, Nabeel, Zhu, Andrew X., Jain, Rakesh K., Duda, Dan G.

“…Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC) but provides limited survival…”
Get full text

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial by Zhu, Andrew X, Dr, Park, Joon Oh, MD, Ryoo, Baek-Yeol, MD, Yen, Chia-Jui, MD, Poon, Ronnie, MD, Pastorelli, Davide, MD, Blanc, Jean-Frederic, MD, Chung, Hyun Cheol, MD, Baron, Ari D, MD, Pfiffer, Tulio Eduardo Flesch, MD, Okusaka, Takuji, MD, Kubackova, Katerina, MD, Trojan, Jorg, MD, Sastre, Javier, PhD, Chau, Ian, MD, Chang, Shao-Chun, MD, Abada, Paolo B, MD, Yang, Ling, MS, Schwartz, Jonathan D, MD, Kudo, Masatoshi, MD

“…Summary Background VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1…”
Get full text

Genetics of Biliary Tract Cancers and Emerging Targeted Therapies by HEZEL, Aram F, DESHPANDE, Vikram, ZHU, Andrew X

“…Biliary tract cancers (BTC), which encompass intra- and extrahepatic cholangiocarcinomas and gallbladder carcinomas, are a genetically diverse collection of…”
Get full text

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression by Fitamant, Julien, Kottakis, Filippos, Benhamouche, Samira, Tian, Helen S., Chuvin, Nicolas, Parachoniak, Christine A., Nagle, Julia M., Perera, Rushika M., Lapouge, Marjorie, Deshpande, Vikram, Zhu, Andrew X., Lai, Albert, Min, Bosun, Hoshida, Yujin, Avruch, Joseph, Sia, Daniela, Campreciós, Genís, McClatchey, Andrea I., Llovet, Josep M., Morrissey, David, Raj, Lakshmi, Bardeesy, Nabeel

“…Defective Hippo/YAP signaling in the liver results in tissue overgrowth and development of hepatocellular carcinoma (HCC). Here, we uncover mechanisms of…”
Get full text